NOXXON's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model
NOXXON Pharma announced that a preclinical study of the SDF-1 inhibiting Spiegelmer NOX-A12 significantly delayed post-irradiation glioblastoma recurrence. The data from this study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.
The study, conducted in collaboration with the Stanford University School of Medicine, investigated the efficacy of NOX-A12 on brain tumor recurrences following irradiation in an animal model. In this model rats begin to die of brain tumors from approximately 120 days of age. These rats were treated with a single dose of whole brain irradiation (20 Gy) which was immediately followed by two different doses of NOX-A12 injected subcutaneously for either 4 or 8 weeks. Neither radiation nor NOX-A12 alone significantly affected the lifespan of the tumor-bearing rats; however the combination of the NOX-A12 (high or low dose) for 8 weeks and irradiation resulted in a significantly prolonged lifespan with the higher dose increasing median lifespan from 189 days for controls to 349 days (P value <0.0001)
NOX-A12 doses and treatment times in this preclinical study were chosen based on equivalents found to be safe and well tolerated in humans. Based on the results obtained from this study, the researchers believe that a clinical trial of NOX-A12 in combination with standard therapy in first-line glioblastoma patients would be justified at this point.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Due to an equipment failure the availability of albumin is currently limited
Global Bioenergies announces break-through in direct biological production of butadiene
Scil Technology Acquires Rights to Worldwide Patents for CD-RAP from Roche Diagnostics GmbH
Global Bioenergies adapts its Bio-Isobutene process to sucrose

Photopharmacology: using light to control cold sensors - Researchers have developed a molecule that allows an important ion channel to be regulated – a breakthrough with therapeutic potential
No new neurons in the human olfactory bulb

Study finds mushroom enzyme effective in combating hepatitis C - White mushroom enzyme has antiviral action against the hepatitis C virus and inhibits its multiplication

Zoom in to watch DNA code being read
Host genome controls skin microbiota and inflammation
Revotar announces promising results suggesting COPD as a potential target for selectin antagonist treatment in humans

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates - Company continues Development of Two Investigational Therapeutic Candidates
